# Safety of ADU-1604 in Adults With Metastatic Melanoma

> **NCT03674502** · PHASE1 · TERMINATED · sponsor: **Aduro Biotech, Inc.** · enrollment: 4 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** ADU-1604

## Key facts

- **NCT ID:** NCT03674502
- **Lead sponsor:** Aduro Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-08
- **Primary completion:** 2019-08-09
- **Final completion:** 2019-08-09
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Study terminated due to business realignment
- **Last updated:** 2020-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03674502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03674502, "Safety of ADU-1604 in Adults With Metastatic Melanoma". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03674502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*